PT  - JOURNAL ARTICLE
AU  - Xi, Jun-Yan
AU  - Zhang, Wang-Jian
AU  - Chen, Zhuo
AU  - Zhang, Yan-Ting
AU  - Chen, Li-Chang
AU  - Zhang, Yu-Qin
AU  - Lin, Xiao
AU  - Hao, Yuan-Tao
TI  - Potential gains in health-adjusted life expectancy by reducing burden of non-communicable diseases: a population-based study
AID  - 10.1101/2022.04.04.22273392
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.04.22273392
4099  - http://medrxiv.org/content/early/2022/04/10/2022.04.04.22273392.short
4100  - http://medrxiv.org/content/early/2022/04/10/2022.04.04.22273392.full
AB  - Background The United Nations Sustainable Development Goals (SDGs) target 3.4 aims to reduce premature mortality attributable to non-communicable diseases (NCDs) by one-third of their 2015 levels by 2030. Although meeting this target leads to longevity, survivors may suffer from long-term disability caused by NCDs. This paper quantifies the potential gains in health-adjusted life expectancy for people aged 30-70 years (HALE[30–70)) by examining the reductions in disability in addition to premature mortality. Additionally, we also assessed the feasibility of meeting the SDGs target 3.4.Methods We extracted data from the Global Burden of Disease Study 2019 for all NCDs and four major NCDs (cancers, cardiovascular diseases, chronic respiratory diseases, and diabetes mellitus) in 188 countries from 1990 to 2019. Bayesian age-period-cohort models were used to predict possible premature mortality in 2030. The life table was used to estimate the unconditional probability of death and HALE[30–70). Estimates of the potential gains in HALE[30–70) were based on three alternative future scenarios: a) eliminating all premature deaths and disability from a specific cause, b) meeting SDGs target 3.4, and survivors’ disability is eliminated, and c) meeting SDGs target 3.4, but survivors remain disabled for the rest of their lives.Results In 2030, the unconditional probability of premature mortality for four major NCDs in most countries remained at more than two-thirds of the 2015 baseline. In all scenarios, the high-income group has the greatest potential gains in HALE[30–70), above the global average of HALE[30–70). In scenario A, the potential gains in HALE[30–70) of reducing premature mortality for four major NCDs are significantly lower than those for all NCDs (range of difference for all income groups: 2.88 - 3.27 years). In scenarios B and C, the potential gains of HALE[30–70) in reducing premature mortality for all NCDs and the four major NCDs are similar (scenario B: 0.14 - 0.22, scenario C: 0.05 - 0.19). In scenarios A and B, countries from the high-income group have the greatest potential gains in HALE[30–70) from cancer intervention, whilst countries from the other income groups result in a greater possible HALE[30–70) gains from cardiovascular diseases control. In scenario C, countries from each income group have the largest potential gains in HALE[30–70) from diabetes reduction and chronic respiratory diseases prevention.Conclusions Achieving SDGs target 3.4 remains challenging for most countries. The elimination of disability among the population who benefit from the target could lead to a sizable improvement in HALE[30–70). Reducing premature death and disability at once and attaching equal importance to each to in line with the WHO goal of “leaving no one behind”.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThis work was supported by a) the Guangdong Basic and Applied Basic Research Foundation (grant 2020A1515011294, 2020A1515110230, and 2021A1515011765); b) the China Postdoctoral Science Foundation (grant 2021M693594). Additionally, Professor Yuantao Hao gratefully acknowledges the support of K.C.Wong Education Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The requirement for ethical board approval was waived because this study is secondary data analysis. All data were aggregated and did not contain any information at the individual levels. Therefore, there were no specific ethical issues warranted special attention.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full dataset in this study can be obtained from the Institute for Health Metrics and Evaluation (https://www.healthdata.org/) and World Population Prospects 2019 (https://population.un.org/wpp/). All data generated during this study are included in the manuscript and supporting files.